Abstract
On May 27, FDA expanded the indication for rimegepant (Nurtec ODT—Biohaven) to include preventive treatment in adults with episodic migraine, defined as fewer than 15 headache days per month. This new indication for rimegepant makes it the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for preventive treatment of migraine and the only migraine medication approved as a dual therapy for acute and preventive treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
